Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report
Year: 2026
Type: article
Study design: Case Report
Abstract: Background Therapeutic options for metallo-β-lactamase (MBL)-producing carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in neonates are extremely limited, particularly after the emergence of polymyxin resistance. Evidence supporting ceftazidime-avibactam (CAZ-AVI) plus aztreonam (ATM) in extremely preterm infants remains scarce. Case Presentation A male infant born at 27 +6 weeks’ gestation with a birth weight of 1,200 g developed perforated necrotizing enterocolitis requiring bowel resection and enterostomy. During hospitalization, he experienced three episodes of NDM-producing CRKP bloodstream infection. The polymyxin B MIC increased from 1 μg/mL in the initial isolate to 4 μg/mL in the third isolate, with the latter result confirmed by repeat broth microdilution testing. Severe intestinal failure-associated liver disease (IFALD) also developed, with a peak direct bilirubin concentration of 426 μmol/L. Synergy testing demonstrated restored activity of CAZ-AVI plus ATM despite resistance to each agent alone. The infant received both CAZ-AVI (50 mg/kg every 8 h) and ATM (30 mg/kg every 8 h) for approximately 7 weeks. Management also included high dose pure fish oil-lipid emulsions (FO-ILE) therapy, anticoagulation guided by thrombotic biomarkers, individualized nutritional support, and delayed intestinal reconstruction. Results Blood cultures and mNGS became negative following combination therapy. After restoration of intestinal continuity, inflammatory markers normalized, cholestasis resolved completely, and full enteral autonomy was achieved. No treatment-related adverse events or renal dysfunction occurred. At 15 months of age (12 months corrected age), growth and neurodevelopment were satisfactory. Conclusion Successful treatment required not only synergistic antimicrobial therapy but also early initiation of oral or enteral feeding through intestinal reconstruction and FO-ILE therapy. This case highlights the importance of integrating antimicrobial, surgical, nutritional strategies in extremely preterm infants with multidrug-resistant infections complicated by intestinal failure and IFALD.
Source: Frontiers in Pharmacology
Authors: Xue Han(Data curation, Writing – original draft), Liang Huang(Formal analysis, Methodology, Writing – review & editing), Xiaoping Jiang(Conceptualization, Investigation, Writing – review & editing), Min Zhang(Data curation, Resources, Writing – original draft), Wei Zhou(Conceptualization, Software, Visualization, Writing – review & editing), Li Zhang(Conceptualization, Project administration, Supervision, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: ceftazidime-avibactam, aztreonam, carbapenem resistance, polymyxin B resistance, extremely preterm infants, necrotizing enterocolitis, bloodstream infection, intestinal failure-associated liver disease, intestinal failure, fish oil lipid emulsion, antimicrobial synergy, intestinal reconstruction
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7237257569
